GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » D. Western Therapeutics Institute Inc (TSE:4576) » Definitions » Debt-to-Equity

D. Western Therapeutics Institute (TSE:4576) Debt-to-Equity : 1.09 (As of Dec. 2024)


View and export this data going back to 2013. Start your Free Trial

What is D. Western Therapeutics Institute Debt-to-Equity?

D. Western Therapeutics Institute's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was 円19.0 Mil. D. Western Therapeutics Institute's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was 円778.9 Mil. D. Western Therapeutics Institute's Total Stockholders Equity for the quarter that ended in Dec. 2024 was 円733.9 Mil. D. Western Therapeutics Institute's debt to equity for the quarter that ended in Dec. 2024 was 1.09.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for D. Western Therapeutics Institute's Debt-to-Equity or its related term are showing as below:

TSE:4576' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.17   Med: 0.41   Max: 1.09
Current: 1.09

During the past 13 years, the highest Debt-to-Equity Ratio of D. Western Therapeutics Institute was 1.09. The lowest was 0.17. And the median was 0.41.

TSE:4576's Debt-to-Equity is ranked worse than
87.6% of 1016 companies
in the Biotechnology industry
Industry Median: 0.14 vs TSE:4576: 1.09

D. Western Therapeutics Institute Debt-to-Equity Historical Data

The historical data trend for D. Western Therapeutics Institute's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

D. Western Therapeutics Institute Debt-to-Equity Chart

D. Western Therapeutics Institute Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Debt-to-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.21 0.17 0.52 0.69 1.09

D. Western Therapeutics Institute Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Dec24
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.50 0.69 1.04 1.30 1.09

Competitive Comparison of D. Western Therapeutics Institute's Debt-to-Equity

For the Biotechnology subindustry, D. Western Therapeutics Institute's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


D. Western Therapeutics Institute's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, D. Western Therapeutics Institute's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where D. Western Therapeutics Institute's Debt-to-Equity falls into.


;
;

D. Western Therapeutics Institute Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

D. Western Therapeutics Institute's Debt to Equity Ratio for the fiscal year that ended in Dec. 2024 is calculated as

D. Western Therapeutics Institute's Debt to Equity Ratio for the quarter that ended in Dec. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


D. Western Therapeutics Institute  (TSE:4576) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.


Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.


D. Western Therapeutics Institute Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of D. Western Therapeutics Institute's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


D. Western Therapeutics Institute Business Description

Traded in Other Exchanges
N/A
Address
7th Floor, 18 KT Bulding, 1-18-11, Nishiki, Naka-ku, Aichi, Nagoyashi, JPN, 460-0003
D. Western Therapeutics Institute Inc is engaged in the research and development of pharmaceutical drugs in Japan. Its products include ophthalmic solution and agents for antiplatelet and anti-glaucoma.

D. Western Therapeutics Institute Headlines

No Headlines